Actualités et vidéos - UCB

Analist Tom Simonts van KBC Securities geeft het antwoord....

New data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference PR Newswire BRUSSELS, March 19, 2025 Clinical data highlight survival benefits and improvement in functional motor outcomes associated with treatment with doxecitine (dC) and doxribtimine (dT) - an investigational pyrimidine nucleoside therapy - in people living with thymidine kinase 2 deficiency (TK2d). 1,2,3 Additional patient experience data emphasize the...

...

Epilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of FINTEPLA® (fenfluramine) in Children and Adults with Dravet Syndrome PR Newswire ATLANTA, March 12, 2025 FINTEPLA is approved by the U.S. Food and Drug Administration (FDA) for the treatment of seizures associated with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) in patients two years of age and older 1 Results showed the most common treatment-emergent adverse events were pyrexia,...

BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden PR Newswire ATLANTA, March 7, 2025 Over half of patients had no draining tunnels (DTs) at two years: In 425 hidradenitis suppurativa (HS) patients with ≥1 DTs at baseline, 55.7% (195/350) had no DTs at two years of treatment. ≠ DTs are painful, pus-discharging tunnels under the skin resulting from long-term inflammation, frequently...

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth PR Newswire ATLANTA, Feb. 27, 2025 Revenue in 2024 increased to € 6.15 billion, a plus of 17% (+19% CER 1 ), Net sales were up by 15% to € 5.61 billion (+17% CER 1 ) driven by a strong, triple- and double-digit growth performance of newly launched growth drivers: BIMZELX ® , EVENITY ® , FINTEPLA ® , RYSTIGGO ® and ZILBRYSQ ® as well as solid contribution from CIMZIA ® and BRIVIACT ® reaching its peak...

Analysons la situation actuelle d'UCB face au retracement de FIBO. Nous discuterons des zones de support cruciales et des ......

UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx) PR Newswire ATLANTA, Jan. 16, 2025 BIMZELX ® (bimekizumab-bkzx) is now commercially available by prescription in the United States in a 2 mL prefilled syringe and autoinjector, each containing 320 mg of BIMZELX The single-injection device offers convenience for patients requiring a 320 mg dose of BIMZELX with single-injection administration ATLANTA , Jan. 16, 2025 /PRNewswire/...

UCB partners with Ailux Biologics, a Division of XtalPi, on Biologics AI Platform PR Newswire CAMBRIDGE, Mass. and BRUSSELS, Jan. 9, 2025 Computational advancements enable earlier and more widespread use of antibody-antigen structural insights across drug discovery process These advancements have the potential to transform antibody discovery methods, broadening therapeutic applications and accelerating the development of innovative molecules CAMBRIDGE, Mass. and BRUSSELS , Jan. 9, 2025...

UCB partners with Ailux Biologics, a Division of XtalPi, on Biologics AI Platform PR Newswire CAMBRIDGE, Mass. and BRUSSELS, Jan. 9, 2025 Computational advancements enable earlier and more widespread use of antibody-antigen structural insights across drug discovery process These advancements have the potential to transform antibody discovery methods, broadening therapeutic applications and accelerating the development of innovative molecules CAMBRIDGE, Mass. and BRUSSELS , Jan. 9, 2025...

UCB Presents New Data on Impact and Burden of Epilepsy at 2024 American Epilepsy Society (AES) Annual Meeting PR Newswire ATLANTA, Dec. 6, 2024 Results of a social media listening study of women of childbearing age with epilepsy underscore the need for HCPs to provide relevant information at critical time points to support shared decision-making 2 A quality-of-life survey administered to caregivers of individuals with developmental and epileptic encephalopathies (DEEs) suggests improved...

UCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual Meeting PR Newswire ATLANTA, Nov. 26, 2024 32 scientific abstracts reflect ongoing commitment to improving outcomes for people living with epilepsies Data include the use of FINTEPLA ® (fenfluramine) 1 oral solution in seizures associated with Dravet syndrome and Lennox-Gastaut syndrome, BRIVIACT ® (brivaracetam) CV 2 and VIMPAT ® (lacosamide) CV 3 in focal-onset seizures, and *Staccato [®]...

Nous explorons comment UCB pourrait rapporter jusqu'à 20% de retour sur investissement. Découvrez les graphiques et les ......

UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis Suppurativa PR Newswire ATLANTA, Nov. 20, 2024 Approval is supported by data from the two Phase 3 studies, BE HEARD I and BE HEARD II, in which BIMZELX ® (bimekizumab-bkzx) improved the signs and symptoms of disease vs. placebo at Week 16, which were sustained to Week 48 Hidradenitis suppurativa is a chronic, painful, and potentially...

New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB's Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis PR Newswire ATLANTA, Nov. 14, 2024 ACR Convergence 2024 marks UCB's first presentation of data in psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS) since the recent approvals of BIMZELX ® (bimekizumab-bkzx) in these indications in the U.S. New two-year...

UCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session PR Newswire BRUSSELS, Oct. 11, 2024 UCB will contribute 14 presentations, including an oral presentation, selected to feature across the AANEM and MGFA meeting, emphasizing UCB's leadership in neuromuscular research Presentations showcase new data for UCB's gMG treatments, including...

Nous explorons les raisons pour lesquelles investir dans UCB pourrait être risqué à ce stade. Le projet est en plein essor depuis ......

UCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis PR Newswire ATLANTA, Sept. 30, 2024 First Phase 3b study in psoriatic arthritis to evaluate the superiority of an IL-17A and IL-17F inhibitor to an IL-23 inhibitor This first head-to-head study in psoriatic arthritis to use ACR50 at Week 16 as a primary endpoint Study underscores UCB's belief in BIMZELX with top-line results expected in 2026 ATLANTA , Sept. 30, 2024...

UCB Announces Late-Breaking Two-Year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024 PR Newswire ATLANTA, Sept. 27, 2024 Clinically meaningful improvements observed with BIMZELX over one year of treatment were maintained up to two years (Week 96) At Week 96, over eight in 10 patients treated with BIMZELX achieved HiSCR50, over seven in 10 achieved HiSCR75, and over four in 10 achieved HiSCR100* Approximately one in three patients treated with...

UCB Presents New 4-year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis at EADV 2024 PR Newswire ATLANTA, Sept. 25, 2024 Responder analyses demonstrated that approximately nine out of 10 patients treated with BIMZELX who achieved PASI90 at Year 1, and over seven out of 10 patients who achieved complete skin clearance (PASI100) at Year 1, maintained this response to Year 4 Switching adalimumab, secukinumab, or ustekinumab PASI90 non-responders to BIMZELX led to most...